Fitzsimons Innovation Community
Fitzsimon_menu

Filter by

GelSana Shares Vision for Innovative Would Care Solutions with Pharmaceutical Executive
News | Sep 18, 2024

GelSana Shares Vision for Innovative Would Care Solutions with Pharmaceutical Executive

In an interview with Pharmaceutical Executive, Melissa Krebs, Ph.D., the CEO and founder of GelSana, discusses her journey in developing novel biomaterials that aim to revolutionize the $78 billion wound care market

EnteroTrack: Tiny Capsule Could Be Game Changer in Gut Health
News | Sep 18, 2024

EnteroTrack: Tiny Capsule Could Be Game Changer in Gut Health

Denver’s 9News recently profiled a biotech entrepreneur leveraging a health innovation developed at Fitzsimons Innovation Community. Robin Shandas, founder and CEO of EnteroTrack, developed the swallowable capsule that collects microbiome samples. Using the capsule, UC Denver graduate student Alex Gregorian founded an early stage startup, BioWell, to make gut health insights more accessible.

Fitzsimons CEO Featured on Healthicity “Compliance Conversations” podcast to Discuss Groundbreaking Ideas Transforming the Future of Healthcare and Medicine
News | Sep 16, 2024

Fitzsimons CEO Featured on Healthicity “Compliance Conversations” podcast to Discuss Groundbreaking Ideas Transforming the Future of Healthcare and Medicine

Fitzsimons Innovation Community CEO Steve VanNurden spoke with CJ Wolfe, M.D., host of Healthicity "Compliance Conversations" podcast, to explore the unique integration of academic and entrepreneurial ecosystems, discuss the reinvention of tech transfer, and reveal the keys to building a thriving biotech community.

Fitzsimons Innovation Community Creates a Hub for Healthcare Tech
News | Aug 19, 2024

Fitzsimons Innovation Community Creates a Hub for Healthcare Tech

Fitzsimons Innovation Community President and CEO Steve VanNurden welcomed Dynamic Tech Media to campus for a conversation about the wrap-around support for our Community members and the growth of life sciences in our state.

GelSana Adds Commercialization Expertise with New Board Director, Diana Verrilli
News | Aug 12, 2024

GelSana Adds Commercialization Expertise with New Board Director, Diana Verrilli

GelSana welcomes Diana Verrilli, Chief Growth Officer at DispatchHealth, to the company’s Board of Directors. Diana, an accomplished healthcare leader brings extensive experience in commercialization and business strategy planning and execution.

CU School of Medicine Boosted to Top-Tier Research Institution by U.S. News
News | Jul 23, 2024

CU School of Medicine Boosted to Top-Tier Research Institution by U.S. News

The University of Colorado School of Medicine at CU Anschutz is a top-tier research institution in the nation, according to U.S. News & World Report. Only 16 medical schools are included in the top tier.

Pioneers in Health Care
News | Jul 22, 2024

Pioneers in Health Care

Fitzsimons Innovation Community is home to more than 80 health and life sciences companies whose live-saving scientific research is blazing the trail for medical advancements and curing diseases, improving patient care, and saving lives. Livability (Adams County) features vignettes of three entrepreneurs conducting groundbreaking research on site.

Fitzsimons Innovation Community Features Among the “Titans of Transformation”
News | Jul 22, 2024

Fitzsimons Innovation Community Features Among the “Titans of Transformation”

Fitzsimons Innovation Community is recognized for having made a profound impact on the region’s economy in the annual issue of Livability (Adams County). Last fall, AC-REP honored Fitzsimons with their Gamechanger award for driving economic vitality.

Atara Biotherapeutics
News | Jul 17, 2024

Atara Biotherapeutics

Today Atara announced that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review with a January 15, 2025 hashtag#PDUFA date for tabelecleucel (tab-cel®) as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (hashtag#EBV) positive post-transplant lymphoproliferative disease (hashtag#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. If approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read the press release for more: https://bit.ly/46bainx

DARTNet enhances and enlarges clinical decision support for clinicians
News | Jul 03, 2024

DARTNet enhances and enlarges clinical decision support for clinicians

DARTNet leaders Wilson Pace and John Westfall co-author "An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD" in International Journal of Chronic Obstructive Pulmonary Disease.

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference
News | Jul 02, 2024

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference

Congratulations to the startup, emerging, and growth companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference, chosen by a panel of experts. Shout out to Fitzsimons Innovation Community Members, EnteroTrack, GelSana, RheumaGen, and Vona Oncology. among those selected.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute
News | Jul 01, 2024

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute

Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.

Load More
© 2024

 Fitzsimons Innovation Community